Group 1A: HR+ Breast Cancer; Hormone & Targeted Therapies; Clinical Trials; Treatment Resistance

Poster #TPS1130: pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2– locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant (adj) endocrine therapy (ET).

Oral Abstract #LBA1001: Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.

Date

Jun 12 2024

Time

10:00 am - 11:30 am

Zoom Webinar

Category
REGISTER